From: Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences
 | RASSF2 | RASSF5A | RASSF1A c |
---|---|---|---|
thyroid cancer cell lines | 7/8 (88%) | 9/9 (100%) | 9/9 (100%) |
primary thyroid cancer | 19/30 (63%)a, b | 26/31 (84%) | 26/31 (84%) |
   MTC | 0/3 (0%) | 1/3 (33%) | 5/6 (83%) |
   PTC | 6/11 (54%) | 9/12 (75%) | 8/13 (62%) |
   FTC | 8/10 (80%) | 10/10 (100%) | 7/10 (70%) |
   UTC | 5/6 (83%) | 6/6 (100%) | 7/9 (77%) |
follicular adenoma | 0/10 (0%)a | 10/10 (100%) | 7/10 (70%) |
goiter | 2/12 (17%)b | 12/12 (100%) | 9/12 (75%) |
control tissue | 0/12 (0%)a | 12/12 (100%) | - |